Vera Therapeutics (NASDAQ:VERA) CEO Sells $701,705.00 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 18,500 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $37.93, for a total transaction of $701,705.00. Following the completion of the sale, the chief executive officer directly owned 198,244 shares of the company’s stock, valued at approximately $7,519,394.92. This represents a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce also recently made the following trade(s):

• On Tuesday, May 12th, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $36.74, for a total transaction of $679,690.00.
• On Tuesday, April 14th, Marshall Fordyce sold 22,951 shares of Vera Therapeutics stock. The stock was sold at an average price of $44.05, for a total transaction of $1,010,991.55.

Vera Therapeutics Stock Performance

Shares of VERA opened at $42.46 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. Vera Therapeutics, Inc. has a one year low of $19.07 and a one year high of $56.05. The company has a 50-day simple moving average of $36.06 and a two-hundred day simple moving average of $41.48. The firm has a market capitalization of $3.05 billion, a PE ratio of -7.66 and a beta of 0.93.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter last year, the company earned ($0.81) earnings per share. On average, analysts anticipate that Vera Therapeutics, Inc. will post -6.23 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on VERA shares. Jefferies Financial Group restated a “buy” rating and set a $60.00 price target on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Evercore set a $91.00 price objective on Vera Therapeutics in a research report on Friday, May 15th. William Blair restated an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Finally, HC Wainwright upped their target price on shares of Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $78.00.

Institutional Investors Weigh In On Vera Therapeutics

Institutional investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its position in shares of Vera Therapeutics by 49.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock worth $276,595,000 after purchasing an additional 1,795,537 shares during the last quarter. Deerfield Management Company L.P. boosted its stake in Vera Therapeutics by 8.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock worth $105,812,000 after purchasing an additional 293,040 shares in the last quarter. Vanguard Group Inc. grew its position in Vera Therapeutics by 11.9% during the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock valued at $180,805,000 after purchasing an additional 379,748 shares during the last quarter. Vestal Point Capital LP grew its position in Vera Therapeutics by 24.0% during the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after purchasing an additional 600,000 shares during the last quarter. Finally, Eversept Partners LP increased its stake in Vera Therapeutics by 9.4% during the 4th quarter. Eversept Partners LP now owns 3,072,304 shares of the company’s stock valued at $155,581,000 after purchasing an additional 264,468 shares in the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.